Amlodipine vs lisinopril
Pro Research Analysisby 
Searched over 200M research papers
Comparative Analysis of Amlodipine vs. Lisinopril in Hypertension Management
Introduction to Amlodipine and Lisinopril
Amlodipine and lisinopril are commonly prescribed medications for managing hypertension. Amlodipine is a calcium channel blocker, while lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. Both drugs have distinct mechanisms of action and are used to reduce blood pressure and prevent cardiovascular events.
Effects on Intima-Media Thickness (IMT)
The ELVERA trial compared the effects of amlodipine and lisinopril on intima-media thickness (IMT) in elderly hypertensive patients. Both drugs significantly reduced IMT over two years, with amlodipine showing a slightly greater reduction in the common carotid artery compared to lisinopril. However, no significant differences were observed in the femoral artery.
Impact on Left Ventricular Mass and Diastolic Function
In the same ELVERA trial, both amlodipine and lisinopril were found to reduce left ventricular mass and improve diastolic function similarly in elderly hypertensive patients. The reductions in left ventricular mass index (LVMI) and improvements in the early to atrial filling ratio (E/A ratio) were comparable between the two drugs.
Blood Pressure Control: Clinic and Ambulatory Measurements
A study comparing the antihypertensive efficacy of amlodipine and lisinopril found that amlodipine was more effective in reducing clinic systolic and diastolic blood pressure than lisinopril. Amlodipine also provided more consistent 24-hour blood pressure control, whereas lisinopril's effect was more pronounced during the daytime.
Combination Therapy in Hypertension Management
Combination therapies involving amlodipine and lisinopril have been explored for enhanced blood pressure control. A study demonstrated that the combination of amlodipine and lisinopril significantly reduced blood pressure compared to monotherapy with either drug alone. This combination was particularly effective in patients with higher baseline blood pressure and those with higher plasma renin activity.
Metabolic and Clinical Outcomes in Metabolic Syndrome
In patients with metabolic syndrome, lisinopril was associated with a lower incidence of newly diagnosed diabetes compared to amlodipine. However, both drugs showed similar cardiovascular outcomes in terms of heart failure and combined cardiovascular disease events. Another study indicated that the combination of lisinopril and amlodipine was effective in reducing blood pressure and proteinuria in patients with essential hypertension.
Renal Outcomes and Proteinuria
A study focusing on nondiabetic renal failure patients found that lisinopril significantly reduced proteinuria, whereas amlodipine did not have a significant effect. Lisinopril also led to a reduction in glomerular filtration rate (GFR), indicating its impact on renal hemodynamics.
Conclusion
Both amlodipine and lisinopril are effective in managing hypertension, with each having unique benefits. Amlodipine provides more consistent 24-hour blood pressure control, while lisinopril is beneficial in reducing proteinuria and has a lower incidence of inducing diabetes in metabolic syndrome patients. Combination therapy with these drugs can offer enhanced blood pressure reduction, making them valuable options in hypertension management. Further research and individualized patient assessment are essential to optimize treatment outcomes.
Sources and full results
Most relevant research papers on this topic